Page 423 - Read Online

Droste et al. J Cancer Metastasis Treat 2023;9:2 https://dx.doi.org/10.20517/2394-4722.2022.94 Page 19 of 22

54. Delaloge S, Hardy-Bessard AC, Bachelot T, et al. First line aromatase inhibitor (AI) + palbociclib with randomized switch to
fulvestrant + palbociclib upon detection of circulating ESR1 mutation in HR+ HER2-metastatic breast cancer patients: Global safety
results of PADA-1, a UCBG-GINECO phase III trial. Cancer Res 2022;82:P1-18-16. DOI
55. Carlson RW. The history and mechanism of action of fulvestrant. Clin Breast Cancer 2005;6:S5-8. DOI PubMed
56. Pike AC, Brzozowski AM, Walton J, et al. Structural insights into the mode of action of a pure antiestrogen. Structure 2001;9:145-53.
DOI PubMed
57. Toy W, Weir H, Razavi P, et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov
2017;7:277-87. DOI PubMed PMC
58. Fanning SW, Greene GL. Next-generation ERα inhibitors for endocrine-resistant ER+ breast cancer. Endocrinology 2019;160:759-
69. DOI PubMed
59. Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy
for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the
randomized phase III EMERALD trial. J Clin Oncol 2022;40:3246-56. DOI PubMed PMC
60. Bihani T, Patel HK, Arlt H, et al. Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in
multiple ER+ breast cancer patient-derived xenograft models. Clin Cancer Res 2017;23:4793-804. DOI PubMed
61. Wardell SE, Nelson ER, Chao CA, Alley HM, McDonnell DP. Evaluation of the pharmacological activities of RAD1901, a selective
estrogen receptor degrader. Endocr Relat Cancer 2015;22:713-24. DOI PubMed PMC
62. Garner F, Shomali M, Paquin D, Lyttle CR, Hattersley G. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader
that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs 2015;26:948-56. DOI PubMed PMC
63. Martin Jimenez M, Lim E, Chavez Mac Gregor M, et al. 211MO giredestrant (GDC-9545) vs physician choice of endocrine
monotherapy (PCET) in patients (pts) with ER+, HER2- locally advanced/metastatic breast cancer (LA/mBC): primary analysis of
the phase II, randomised, open-label acelERA BC study. Ann Oncol 2022;33:S633-4. DOI
64. Tolaney S, Chan A, Petrakova K, et al. 212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of
physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2- advanced breast cancer (aBC). Ann Oncol
2022;33:S634-5. DOI
65. Linden HM, Campone M, Bardia A, et al. Abstract PD8-08: a phase 1/2 study of SAR439859, an oral selective estrogen receptor
(ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-
positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1. Cancer
Res 2021;81:PD8-08. DOI
66. Bardia A, Linden HM, Ulaner GA, et al. Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader
(SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC). JCO 2019;37:1054. DOI
67. Bardia A, Cortes J, Hurvitz SA, et al. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus
letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer. Ther Adv Med Oncol
2022;14:17588359221083956. DOI PubMed PMC
68. Sanofi provides update on amcenestrant clinical development program - sanofi. Available from: https://www.sanofi.com/en/media-
room/press-releases/2022/2022-08-17-05-30-00-2499668 [Last accessed on 16 Feb 2023].
69. Rusquec P, Blonz C, Frenel JS, Campone M. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative
advanced breast cancer. Ther Adv Med Oncol 2020;12:1758835920940939. DOI PubMed PMC
70. Thangavel C, Dean JL, Ertel A, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant
breast cancer. Endocr Relat Cancer 2011;18:333-45. DOI PubMed PMC
71. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J
Med 2012;366:520-9. DOI
+ -
72. Beck JT, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR , HER2 advanced breast cancer
in BOLERO-2. Breast Cancer Res Treat 2014;143:459-67. DOI PubMed PMC
73. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer:
BOLERO-2 final progression-free survival analysis. Adv Ther 2013;30:870-84. DOI PubMed PMC
74. Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth
factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 2014;25:2357-62. DOI
PubMed PMC
75. Im YH, Karabulut B, Lee KS, et al. Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with
locally advanced or metastatic breast cancer: final results from EVEREXES. Breast Cancer Res Treat 2021;188:77-89. DOI
PubMed
76. Lousberg L, Jerusalem G. Safety, efficacy and patient acceptability of everolimus in the treatment of breast cancer. Breast Cancer
2016;10:239-52. DOI PubMed PMC
77. Mo H, Renna CE, Moore HCF, et al. Real-world outcomes of everolimus and exemestane for the treatment of metastatic hormone
receptor-positive breast cancer in patients previously treated with CDK4/6 inhibitors. Clin Breast Cancer 2022;22:143-8. DOI
PubMed
78. Cook MM, Al Rabadi L, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI. Everolimus plus exemestane treatment in patients with
metastatic hormone receptor-positive breast cancer previously treated with CDK4/6 inhibitor therapy. Oncologist 2021;26:101-6.